pharma · Asthma · Respiratory Syncytial Virus Infections
GSK Glaxo Smith
GlaxoSmithKline
GSK Glaxo Smith is a pharma organization headquartered in SAINT-AMAND LES EAUX, FR. Primary therapeutic focus areas include Asthma, Respiratory Syncytial Virus Infections, Hepatitis B, Chronic, Neoplasms, Influenza. Nova
Company details
- Status
- Public
- HQ
- 637 r Aulnois, Saint Amand les Eaux, 59 59230, FR, SAINT-AMAND LES EAUX
- Employees
- 30
- Programs
- 205
- Drugs
- 194
- Patents
- 0
Quick answer
GSK Glaxo Smith is a pharma organization headquartered in SAINT-AMAND LES EAUX, FR. Primary therapeutic focus areas include Asthma, Respiratory Syncytial Virus Infections, Hepatitis B, Chronic, Neoplasms, Influenza. NovaPharmaNews links 205 clinical program(s), 17 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (86), phase 2 (70), phase 1 (34).
Company snapshot
GSK Glaxo Smith maintains 205 tracked programs across Asthma, Respiratory Syncytial Virus Infections, Hepatitis B, Chronic, Neoplasms, Influenza, Systemic Lupus Erythematosus, Pulmonary Disease, Chronic Obstructive, Lung Cancer, Non-Small Cell, Multiple Myeloma, Infections, Meningococcal, Hepatitis B, Diabetes Mellitus, Type 2. Momentum score: 35/100 (30-day delta: n/a). Public registry data cover
- 12 approved product(s) across US/EU regulatory metadata.
- 205 active pipeline program(s) linked via ClinicalTrials.gov.
- 205 trial update(s) in the last 12 months.
Public regulatory, clinical, patent, and corporate records for GSK Glaxo Smith. Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- approval
GSK and Alfasigma Licensing Agreement, Servier's $2.5B Acquisition
- approval
Friday Five: Key Regulatory Updates in Pharma
- approval
Moderna mRNA-1083 Phase 3 data show stronger flu and COVID immune response
- approval
GSK Blenrep wins FDA approval in relapsed multiple myeloma
- approval
Moderna's mRNA-1083 Phase 3 shows stronger flu and COVID immune responses
- approval
GSK’s Blenrep returns to the US market after FDA approves resubmission
Recent coverage
GSK’s Blenrep returns to the US market after FDA approves resubmission
The FDA has approved GSK’s Blenrep in combination with bortezomib and dexamethasone, clearing the drug’s return to the US market. The move ends a withdrawal that followed a failed confirmatory study and resets the catalyst timeline for investors and BD teams.
Moderna mRNA-1083 Phase 3 data show stronger flu and COVID immune response
Moderna says its combined flu-COVID vaccine mRNA-1083 met Phase 3 primary endpoints with higher immune responses in adults 50 and older. The readout matters for BD teams and investors tracking combo-vaccine competition, FDA posture, and next filing milestones.
GSK Blenrep wins FDA approval in relapsed multiple myeloma
GSK’s Blenrep has returned to the U.S. market after the FDA approved it in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma. The catalyst matters for BD teams and investors because it reverses a prior withdrawal and resets the drug’s U.S. label and commercial outlook.
Friday Five: Key Regulatory Updates in Pharma
This article covers significant regulatory updates impacting the pharmaceutical industry, including GSK's breakthrough in hepatitis B and Eli Lilly's advancements in prevention.
Top assets
Lead pipeline drugs
- Marketed / approved
- approved
- approved
- approved
Momentum
Proprietary activity score for GSK Glaxo Smith.
2 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Competitor landscape
Therapeutic-area overlap peers from registry and pipeline signals.
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
Recent activity
Latest pipeline, patent, and corporate events for GSK Glaxo Smith.
- Clinical update
- Clinical update
- Clinical update
- Clinical update
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is GSK Glaxo Smith?
-
Is GSK Glaxo Smith publicly traded?
-
What drugs does GSK Glaxo Smith develop or market?
-
What are the latest developments for GSK Glaxo Smith?
-
What therapeutic areas does GSK Glaxo Smith focus on?
Full intelligence profile
Registry synthesis
Grounded overview from trials, patents, coverage, and catalysts.
GSK Glaxo Smith maintains 205 tracked programs across Asthma, Respiratory Syncytial Virus Infections, Hepatitis B, Chronic, Neoplasms, Influenza, Systemic Lupus Erythematosus, Pulmonary Disease, Chronic Obstructive, Lung Cancer, Non-Small Cell, Multiple Myeloma, Infections, Meningococcal, Hepatitis B, Diabetes Mellitus, Type 2. Momentum score: 35/100 (30-day delta: n/a).
Public registry data covers pipeline phase, clinical trials, patents, SEC filings, and Nova editorial coverage. HQ: SAINT-AMAND LES EAUX FR. Ticker: ED9AA7C.
Pipeline programs
Cervarix™ — phase phase_3, status completed. Indication: Infections, Papillomavirus. Next milestone: not disclosed (TBD).
eltrombopag — phase phase_3, status completed. Indication: Purpura, Thrombocytopaenic, Idiopathic. Next milestone: not disclosed (TBD).
213410 — phase phase_3, status active. Indication: Lung Cancer, Non-Small Cell. Next milestone: not disclosed (TBD).
Bepirovirsen — phase phase_3, status completed. Indication: Chronic Hepatitis B. Next milestone: not disclosed (TBD).
Dostarlimab — phase phase_3, status active. Indication: Neoplasms, Head and Neck. Next milestone: not disclosed (TBD).
eltrombopag — phase phase_3, status completed. Indication: Hepatitis C, Chronic. Next milestone: not disclosed (TBD).
MEPOLIZUMAB — phase phase_3, status active. Indication: Hypereosinophilic syndrome (HES). Next milestone: not disclosed (TBD).
213400 — phase phase_3, status active. Indication: Lung Cancer, Non-Small Cell. Next milestone: not disclosed (TBD).
214828 — phase phase_3, status active. Indication: Multiple myeloma. Next milestone: not disclosed (TBD).
albiglutide + insulin glargine — phase phase_3, status completed. Indication: Diabetes Mellitus, Type 2. Next milestone: not disclosed (TBD).
denosumab — phase phase_3, status completed. Indication: Osteoporosis, Postmenopausal. Next milestone: not disclosed (TBD).
Salbutamol HFA-134a — phase phase_3, status completed. Indication: Asthma. Next milestone: not disclosed (TBD).
Recent Nova coverage
Nova coverage: GSK’s Blenrep returns to the US market after FDA approves resubmission (2026-06-07).
Nova coverage: Moderna mRNA-1083 Phase 3 data show stronger flu and COVID immune response (2026-06-07).
Nova coverage: GSK Blenrep wins FDA approval in relapsed multiple myeloma (2026-06-07).
Nova coverage: Moderna's mRNA-1083 Phase 3 shows stronger flu and COVID immune responses (2026-06-07).
Nova coverage: Friday Five: Key Regulatory Updates in Pharma (2026-05-31).
Nova coverage: GSK and Ionis Present Promising Hepatitis B Drug Data (2026-05-29).
Nova coverage: GSK and Alfasigma Licensing Agreement, Servier's $2.5B Acquisition (2026-05-29).
Nova coverage: AbbVie and GSK's Rise in Patient Reputation: Insights for Pharma (2026-05-23).
Registry facts
Registry profile: founded unknown; employees 30; market cap n/a; revenue n/a; LEI 213800NQEFE4U61TAB32; CIK n/a.
Company type: pharma; public/private: public. Data quality score: 0.800.
Catalyst calendar
Catalyst: GSK and Alfasigma Licensing Agreement, Servier's $2.5B Acquisition — type approval, date 2026-05-29.
Catalyst: Friday Five: Key Regulatory Updates in Pharma — type approval, date 2026-05-31.
Catalyst: Moderna mRNA-1083 Phase 3 data show stronger flu and COVID immune response — type approval, date 2026-06-07.
Catalyst: GSK Blenrep wins FDA approval in relapsed multiple myeloma — type approval, date 2026-06-07.
Catalyst: Moderna's mRNA-1083 Phase 3 shows stronger flu and COVID immune responses — type approval, date 2026-06-07.
Catalyst: GSK’s Blenrep returns to the US market after FDA approves resubmission — type approval, date 2026-06-07.
Competitive peers
Peer: Boehringer Ingelheim (overlap score 50.0).
Peer: Teva Pharma (overlap score 40.0).
Peer: Chongqing Precision Biotech (overlap score 40.0).
Peer: AstraZeneca (overlap score 40.0).
Peer: Novartis India (overlap score 40.0).
Peer: Janssen Cilag International (overlap score 39.2).
Peer: Sanofi Pasteur MSD (overlap score 36.6).
Peer: Arrowhead Pharmaceuticals Ireland (overlap score 32.6).
Competitive positioning reflects therapeutic-area overlap with peer sponsors and recent catalyst activity from trials, regulatory actions, and congress presentations. Data is assembled from ClinicalTrials.gov, SEC EDGAR, openFDA, and NovaPharmaNews articles — not third-party wire republication.
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.